摘要
目的总结分析低分子肝素钙联合沙美特罗替卡松气雾剂(舒利迭)(吸入)治疗急性加重期COPD的临床效果。方法选取我院2017年1—8月收治的120例急性加重期COPD患者作为研究对象。其中,对照组60例采用舒利迭吸入治疗,观察组60例采用舒利迭吸入联合低分子肝素钙治疗,比较两组患者的治疗效果。结果观察组患者治疗后FEV1、FVC以及FEV1/FVC等肺功能指标优于对照组的上述指标,差异具有统计学意义(P<0.05)。结论低分子肝素钙联合舒利迭吸入治疗急性加重期COPD,能够有效改善患者的肺部功能指标,效果明显。
Objective To summarize and analyze the clinical efect of low molecular weight heparin calcium combined with salmeterol xinafoate and fluticasone propionate aerosol （seretide） in the treatment of acute exacerbation of COPD. Methods 120 patients with acute exacerbation of COPD treated in our hospital from January to August 2017 were selected as the research subjects. Among them, 60 patients in the control group were treated with inhalation of seretide. In the observation group, 60 cases were treated with Seretide inhalation combined with low molecular weight heparin calcium. The therapeutic efects of the two groups were compared. Results The indexes of FEV1, FVC and FEV1/FVC in the observation group were better than those in the control group, and the diference was statistically significant （P 〈 0.05）. Conclusion Low molecular weight heparin combined with seretide inhalation of acute exacerbation of COPD, the efect is obvious.
作者
邢丽莉
申力
XING Lili;SHEN Li(Department of Internal Medicine, Tieying Hospital at Fengtai District, Beijing 100079, China;Department of Surgery)
出处
《中国继续医学教育》
2018年第15期126-127,共2页
China Continuing Medical Education
关键词
低分子肝素钙
沙美特罗替卡松气雾剂
联合治疗
急性加重期COPD
临床效果
low molecular weight heparin
salmeterol xinafoate and fluticasone propionate aerosol
combination therapy
acute exacerbation COPD
clinical efect
